Search
NS-3728
go.drugbank.com/drugs/DB05835ExperimentalNS3728 is an orally active chloride channel blocker for the treatment of cancer.
Synonyms: N-[4-bromo-2-(1H-1,2,3,4-tetrazol-5-yl)phenyl]-N'-[3,5-bis(trifluoromethyl)phenyl]ureaFormebolone
go.drugbank.com/drugs/DB01569IllicitInvestigationalFormebolone, a derivative of androstane, is an anabolic androgenic steroid. It is on the list of substances prohibited by the Word Anti-Doping Agency, and is regularly screened for in athletes. It is also classified by the US Drug Enforc...
Caprospinol
go.drugbank.com/drugs/DB05263ExperimentalCaprospinol (SP-233) is the first drug ever to demonstrate the correlation of clearing beta-amyloid from the brain. It also improves the brain histopathology and recovers memory function.
Corticosterone
go.drugbank.com/drugs/DB04652Investigational(From Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p1437)
Enviomycin
go.drugbank.com/drugs/DB08993ExperimentalIt is isolated from an induced mutant of Streptomyces griseoverticillatus var. tuberacticus and acts as an antitubercular agent with less ototoxicity than tuberactinomycin.
Synonyms: Tuberactinomycin NWP-1301
go.drugbank.com/drugs/DB17702ExperimentalWP1301 is a synthetic peptide derived from hFVIII. It binds to an MHC class II molecule and is recognized by a Factor VIII-specific T cell.[L46138]
Tiapride
go.drugbank.com/drugs/DB13025InvestigationalTiapride is a selective D2 and D3 dopamine receptor blocker in the brain.
Taberminogene vadenovec
go.drugbank.com/drugs/DB05011ExperimentalEG004 has completed a Phase II trial, this being the first part of the Phase II/III study for which it has received approval from the US Recombinant DNA Advisory Committee (RAC).
Phentermine
go.drugbank.com/drugs/DB00191ApprovedIllicitInvestigationalPhentermine is a sympathomimetic amine anorectic agent and it was introduced in 1959 as part of an anti-obesity combination drug. It is chemically related to amphetamine and it is commonly referred to as an atypical amphetamine. Phenterm...